RxDoctor Payments Data

Amir Ausef, MD

Internal Medicine · Baton Rouge, LANPI 1528046315

Payments from drug & device makers

$1,120in general payments, 2019–2025

Across 52 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$270
  • AstraZeneca$263
  • Acadia Pharmaceuticals Inc$211
  • E.r. Squibb & Sons, L.L.C.$158
  • KCI USA, Inc.$125
  • Pfizer$46
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$1,02191%
  • Education$999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,120 in reported general payments places this provider in the 65th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$311,703
Medicare patients
795
Services billed
3,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala22$93,005
EliquisApixaban318$91,733
RestasisCyclosporine69$45,526
XareltoRivaroxaban135$45,500
MyrbetriqMirabegron134$30,821
JardianceEmpagliflozin90$26,796
IsentressRaltegravir Potassium25$24,887
GemtesaVibegron94$22,859
LinzessLinaclotide38$21,676
EntrestoSacubitril/Valsartan74$21,414
SantylCollagenase Clostridium Hist.55$17,619
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc162$16,146
Etravirine12$15,900
Abacavir-LamivudineAbacavir Sulfate/Lamivudine12$13,053
RexultiBrexpiprazole18$12,827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$91,733318 claims
Johnson & JohnsonXarelto$270$45,500135 claims
MerckIsentress, Januvia$16$35,90065 claims
NovartisEntresto$13$21,41474 claims
AstraZenecaBrilinta$263$7,23233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →